NASDAQ:STRO - Sutro Biopharma Stock Price, Forecast & News

Sutro Biopharma's stock was trading at $8.11 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, STRO stock has increased by 20.7% and is now trading at $9.79. View which stocks have been mosted impacted by Coronavirus.

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Sutro Biopharma in the last year. There are currently 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Sutro Biopharma.

Sutro Biopharma is scheduled to release its next quarterly earnings announcement on Wednesday, May 20th 2020. View our earnings forecast for Sutro Biopharma.

Sutro Biopharma Inc (NASDAQ:STRO) issued its quarterly earnings data on Monday, March, 16th. The company reported ($0.64) EPS for the quarter, beating the consensus estimate of ($0.69) by $0.05. The firm earned $11.31 million during the quarter, compared to the consensus estimate of $9.33 million. View Sutro Biopharma's earnings history.

7 analysts have issued 1 year target prices for Sutro Biopharma's stock. Their forecasts range from $16.00 to $22.00. On average, they expect Sutro Biopharma's share price to reach $18.60 in the next twelve months. This suggests a possible upside of 90.0% from the stock's current price. View analysts' price targets for Sutro Biopharma.

Press coverage about STRO stock has been trending somewhat negative this week, according to InfoTrie. The research firm rates the sentiment of press coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Sutro Biopharma earned a news sentiment score of -1.5 on InfoTrie's scale. They also gave headlines about the company a news buzz of 2.0 out of 10, indicating that recent press coverage is very unlikely to have an impact on the stock's share price in the immediate future. View the latest news aboutSutro Biopharma.

Sutro Biopharma saw a increase in short interest during the month of March. As of March 13th, there was short interest totaling 68,900 shares, an increase of 53.8% from the February 27th total of 44,800 shares. Based on an average daily volume of 23,800 shares, the short-interest ratio is currently 2.9 days. Currently, 0.8% of the company's shares are sold short. View Sutro Biopharma's Current Options Chain.

Some companies that are related to Sutro Biopharma include Beam Therapeutics (BEAM), Adverum Biotechnologies (ADVM), Sangamo Therapeutics (SGMO), Oyster Point Pharma (OYST), Krystal Biotech (KRYS), Orchard Therapeutics (ORTX), Novavax (NVAX), Osiris Therapeutics (OSIR), AVITA MED LTD/S (AVMXY), Translate Bio (TBIO), Aerie Pharmaceuticals (AERI), AVITA MED LTD/S (RCEL), Passage Bio (PASG), Atara Biotherapeutics (ATRA) and GENFIT S A/ADR (GNFT).

Based on aggregate information from My MarketBeat watchlists, some companies that other Sutro Biopharma investors own include Agile Therapeutics (AGRX), Anavex Life Sciences (AVXL), Crispr Therapeutics (CRSP), Sorrento Therapeutics (SRNE), Momo (MOMO), Vaxart (VXRT), AcelRx Pharmaceuticals (ACRX), Aduro BioTech (ADRO), Amarin (AMRN) and Fortress Biotech (FBIO).

(STRO) raised $75 million in an initial public offering on Thursday, September 27th 2018. The company issued 5,000,000 shares at $14.00-$16.00 per share. Cowen and Piper Jaffray served as the underwriters for the IPO and JMP Securities and Wedbush PacGrow were co-managers.

Sutro Biopharma trades on the NASDAQ under the ticker symbol "STRO."

Sutro Biopharma's stock is owned by a variety of retail and institutional investors. Top institutional investors include Eventide Asset Management LLC (5.39%), BVF Inc. IL (1.50%), Driehaus Capital Management LLC (1.22%), State Street Corp (0.73%), FMR LLC (0.69%) and Granite Point Capital Management L.P. (0.43%). Company insiders that own Sutro Biopharma stock include Daniel H Petree, Merck & Co, Inc and Trevor Hallam. View institutional ownership trends for Sutro Biopharma.

STRO stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, Creative Planning, Victory Capital Management Inc., and Nuveen Asset Management LLC. View insider buying and selling activity for Sutro Biopharma.

STRO stock was acquired by a variety of institutional investors in the last quarter, including Eventide Asset Management LLC, Granite Point Capital Management L.P., Victory Capital Management Inc., Jacobs Levy Equity Management Inc., Janus Henderson Group PLC, Spark Investment Management LLC, Acadian Asset Management LLC, and Oxford Asset Management LLP. View insider buying and selling activity for Sutro Biopharma.

Shares of STRO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of STRO stock can currently be purchased for approximately $9.79.

Sutro Biopharma has a market capitalization of $226.15 million and generates $42.74 million in revenue each year. The company earns $-55,740,000.00 in net income (profit) each year or ($2.43) on an earnings per share basis. Sutro Biopharma employs 141 workers across the globe. View additional information about Sutro Biopharma.

The official website for Sutro Biopharma is http://www.sutrobio.com/.

Sutro Biopharma's mailing address is 310 Utah Avenue Suite 150, South San Francisco CA, 94080. The company can be reached via phone at 650-392-8412.